Nothing Special   »   [go: up one dir, main page]

CO2023014715A2 - Use of medication in the treatment of tumor disease - Google Patents

Use of medication in the treatment of tumor disease

Info

Publication number
CO2023014715A2
CO2023014715A2 CONC2023/0014715A CO2023014715A CO2023014715A2 CO 2023014715 A2 CO2023014715 A2 CO 2023014715A2 CO 2023014715 A CO2023014715 A CO 2023014715A CO 2023014715 A2 CO2023014715 A2 CO 2023014715A2
Authority
CO
Colombia
Prior art keywords
cancer
treatment
tumor disease
tumor
medication
Prior art date
Application number
CONC2023/0014715A
Other languages
Spanish (es)
Inventor
Jingyi Wang
Junyou Ge
Xuenong Ouyang
Xiaoping Jin
Yina Diao
Gesha Liu
Yezhe Cheng
Ying Xu
Chun Rao
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CO2023014715A2 publication Critical patent/CO2023014715A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere al uso de un medicamento en el tratamiento de una enfermedad tumoral. En particular, la presente invención proporciona el uso de un conjugado biológicamente activo representado por la fórmula (I) en el tratamiento de una enfermedad tumoral. La enfermedad tumoral se refiere particular y preferiblemente a un tumor sólido metastásico o localmente avanzado irresecable que es refractario según los estándares de tratamiento existentes, incluyendo, entre otros, cáncer de mama, cáncer gástrico, cáncer de pulmón, cáncer de ovario, cáncer epitelial del tracto urinario, cáncer de esófago, cáncer de hígado, cáncer colorrectal, cáncer de cuello uterino, cáncer de endometrio, cáncer de páncreas y tumor cerebral.The present invention relates to the use of a medication in the treatment of a tumor disease. In particular, the present invention provides the use of a biologically active conjugate represented by formula (I) in the treatment of a tumor disease. Tumor disease particularly and preferably refers to an unresectable locally advanced or metastatic solid tumor that is refractory according to existing treatment standards, including, but not limited to, breast cancer, gastric cancer, lung cancer, ovarian cancer, epithelial cancer of the urinary tract, esophageal cancer, liver cancer, colorectal cancer, cervical cancer, endometrial cancer, pancreatic cancer and brain tumor.

CONC2023/0014715A 2021-04-30 2023-10-30 Use of medication in the treatment of tumor disease CO2023014715A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110482012 2021-04-30
PCT/CN2022/089737 WO2022228497A1 (en) 2021-04-30 2022-04-28 Use of medicament in treatment of tumor disease

Publications (1)

Publication Number Publication Date
CO2023014715A2 true CO2023014715A2 (en) 2024-02-05

Family

ID=83846722

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0014715A CO2023014715A2 (en) 2021-04-30 2023-10-30 Use of medication in the treatment of tumor disease

Country Status (14)

Country Link
US (1) US20240238434A1 (en)
EP (1) EP4331614A1 (en)
JP (1) JP2024516217A (en)
KR (1) KR20240004657A (en)
CN (1) CN117157106A (en)
AU (1) AU2022263701A1 (en)
BR (1) BR112023022540A2 (en)
CA (1) CA3217111A1 (en)
CL (1) CL2023003211A1 (en)
CO (1) CO2023014715A2 (en)
EC (1) ECSP23082749A (en)
IL (1) IL308098A (en)
MX (1) MX2023012797A (en)
WO (1) WO2022228497A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024175042A1 (en) * 2023-02-24 2024-08-29 四川科伦博泰生物医药股份有限公司 Use of drug conjugate in treatment of tumor disease and method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200099123A (en) * 2017-12-15 2020-08-21 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 Bioactive conjugate, preparation method and use thereof
CN110903395A (en) * 2018-09-14 2020-03-24 四川科伦博泰生物医药股份有限公司 Antibody, conjugate, preparation method and application thereof

Also Published As

Publication number Publication date
CA3217111A1 (en) 2022-11-03
IL308098A (en) 2023-12-01
WO2022228497A1 (en) 2022-11-03
EP4331614A1 (en) 2024-03-06
MX2023012797A (en) 2024-02-06
CL2023003211A1 (en) 2024-07-12
JP2024516217A (en) 2024-04-12
US20240238434A1 (en) 2024-07-18
BR112023022540A2 (en) 2024-01-02
AU2022263701A1 (en) 2023-11-09
KR20240004657A (en) 2024-01-11
ECSP23082749A (en) 2023-11-30
CN117157106A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
AR070865A1 (en) COMBINATIONS OF AN ANTIBODY-ANTI-HER2 PHARMACO AND CHEMOTHERAPEUTIC AGENTS AND METHODS OF USE
EA202092320A1 (en) HETEROBICYCLIC MAT2A INHIBITORS AND METHODS OF USE FOR TREATMENT OF MALIGNANT TUMOR
US20190375704A1 (en) Modulators of the eif2alpha pathway
AR059982A1 (en) TUMOR THERAPY WITH AN ANTIBODY AGAINST THE VASCULAR ENDOTELIAL GROWTH FACTOR AND AN ANTIBODY AGAINST THE HUMAN TYPE 2 EPITELIAL GROWTH FACTOR RECEIVER
RU2014108045A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF A MALIGNANT TUMOR
RU2014108043A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF A MALIGNANT TUMOR
CO2023014715A2 (en) Use of medication in the treatment of tumor disease
BRPI0601736A (en) adjuvant therapy methods, nonmetastatic breast cancer cure method, disease recurrence reduction method, instruction method of human patients with non-metastatic her2-positive breast cancer, production method and commercial methods
DOP2015000244A (en) NEW COMPOUNDS AS REORGANIZED INHIBITORS DURING TRANSFECTION (RET)
ES2534430T3 (en) Modulation method of epidermal growth factor receptor (EGFR) expression that involves miRNA
EP4324460A3 (en) Sodium bicarbonate for use in the treatment of gout and related disorders
UY31757A1 (en) COMBINATION OF THE HGF INHIBITOR AND THE EGF INHIBITOR FOR CANCER TREATMENT
CR20220626A (en) 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
JP2019526560A5 (en)
EA201492004A1 (en) ORGANIC COMPOSITIONS FOR THE TREATMENT OF KRAS-ASSOCIATED DISEASES
TW201613589A (en) Combination methods for treating cancers
RU2010140890A (en) IMPROVED METHODS OF ANTITUMOR TREATMENT
RS20080002A (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
MX2021014524A (en) Methods of treating urinary system cancers.
TWI787201B (en) Antitumor agent, antitumor effect enhancer, and antitumor kit
MX2020012611A (en) High surface-area lyophilized compositions comprising arsenic for oral administration in patients.
EA201171360A1 (en) ANTI-TUMOR COMPLEX, CONTAINING CABAZITAXEL AND CAPETITABINS
RU2010119922A (en) ADVANCED ANTITUMOR TREATMENT
BR112022009798A2 (en) RECOMBINANT MVA VIRUS FOR INTRATUMORAL AND/OR INTRAVENOUS ADMINISTRATION FOR CANCER TREATMENT
EA202190614A1 (en) Conjugate of paclitaxel and hyaluronic acid in the treatment of non-invasive muscular bladder cancer